BioSpace News Archive

MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) announced that positive 12-week results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (“HS”) were presented today during a late-breaking session at the European Academy of Dermatology and Venereology Congress (“EADV”) held in Berlin, Germany.

Incyte (Nasdaq:INCY) today announced new results of a pooled analysis of long-term extension (LTE) data from the pivotal Phase 3 TRuE-V program assessing Opzelura® (ruxolitinib) cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo who previously experienced limited or no response to treatment at Week 24.

eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, today announced publication in the journal Nature of long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model.

Femasys Inc. announced that it has it has received notice from The Nasdaq Stock Market LLC informing Femasys that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

Kazia Therapeutics Limited, an oncology-focused drug development company, announces its intention to de-list from the Australian Securities Exchange.

Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy leader Bristol Myers Squibb will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy, as part of the Cellares Technology Adoption Partnership program.

Glaukos Corporation plans to release third quarter 2023 financial results after the market close on Wednesday, November 1, 2023.

Shionogi & Co., Ltd. announced that it will present real-world evidence suggesting treatment with Fetroja® is effective in treating Gram-negative infections and that appropriate patients who received Fetroja earlier had lower in-hospital all-cause mortality than those receiving it later.1 The data are being presented at IDWeek 2023, which is taking place in Boston, October 11-15.

Paradigm BioDevices, “The Leader in MIS Bone Graft Harvesting,” is pleased to announce the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System.

STEMCELL Technologies, Canada’s largest biotechnology company, is releasing its first annual sustainability report today.